Cambridge, MA – Anchor Line Partners, LLC and partner Northwood Investors, LLC announced a construction milestone for 60 First Street in East Cambridge.
The team recently celebrated the topping off of the life sciences project, located at the former Sears building within the Cambridgeside 2.0 redevelopment. Anchor Line also announced that, ahead of completion, 60 First Street is now 100% leased.
Located at the intersection of First and Thorndike, and situated on the newly revitalized Lechmere MBTA station, 60 First Street is currently undergoing a build out of the existing three stories, as well as a 2-story expansion. Upon completion, the building will offer Class A lab/office space, ground-floor retail space, and a new walkway connecting to the Cambridgeside 2.0 ecosystem in the East Cambridge/Kendall Square neighborhood.
Before placing the final steel beam, Anchor Line welcomed two tenants to the 60 First Street community. Prime Medicine, a biotech startup focused on gene editing, announced earlier this year that it will occupy three floors and approximately 148,000sf of the redevelopment. Korro Bio, an RNA editing company focused on the discovery and development of novel genetic medicines, recently announced it will occupy 50,000sf at 60 First Street.
“East Cambridge continues to prove to be the nexus for finding cures to disease and improving the quality of life for people. It is our mission to provide these companies that are on the frontier of change the environments they need to succeed,” said Andrew Maher, managing director at Anchor Line Partners. “We are thrilled to welcome Prime Medicine and Korro Bio to 60 First Street.”
Gilbane Building Company is the general contractor on the redevelopment.
“We’re excited to move forward with plans to relocate Korro’s corporate headquarters to the 60 First Street development in mid-2023. The company continues to grow and we anticipate having over 100 employees collaborating in this dynamic, cutting-edge space, in the heart of the reimagined Cambridgeside area,” said Anna Barry, COO of Korro Bio.